Antiviral and Immunomodulatory Properties of Antimicrobial Peptides Produced by Human Keratinocytes.
Chessa. Céline C; Bodet. Charles C; Jousselin. Clément C; Wehbe. Michel M; Lévêque. Nicolas N; Garcia. Magali M
Key Findings
- Keratinocytes produce LL‑37 and several other antimicrobial peptides
- LL‑37 can directly inactivate viral particles and interfere with their replication
- LL‑37 also modulates immune signaling, boosting antiviral defenses
Practical Outcomes
- While LL‑37 isn’t a typical supplement, the data suggest that supporting skin health (e.g., vitamin D to raise LL‑37 levels) or using topical LL‑37‑based products could add antiviral protection. For biohackers, the main takeaway is that enhancing natural peptide production may be a low‑risk way to bolster innate immunity.
Summary
Human skin cells make a peptide called LL‑37 that can both kill viruses directly and help the immune system fight them. This review gathers evidence that LL‑37 and other skin‑made peptides work against many common viruses.
Abstract
Keratinocytes, the main cells of the epidermis, are the first site of replication as well as the first line of defense against many viruses such as arboviruses, enteroviruses, herpes viruses, human papillomaviruses, or vaccinia virus. During viral replication, these cells can sense virus associated molecular patterns leading to the initiation of an innate immune response composed of pro-inflammatory cytokines, chemokines, and antimicrobial peptides. Human keratinocytes produce and secrete at least nine antimicrobial peptides: human cathelicidin LL-37, types 1-4 human β-defensins, S100 peptides such as psoriasin (S100A7), calprotectin (S100A8/9) and koebnerisin (S100A15), and RNase 7. These peptides can exert direct antiviral effects on the viral particle or its replication cycle, and indirect antiviral activity, by modulating the host immune response. The purpose of this review is to summarize current knowledge of antiviral and immunomodulatory properties of human keratinocyte antimicrobial peptides.
Study Information
pubmed
2020
2020-06-03T00:00:00.000Z
10.3389/fmicb.2020.01155
77
182